Pharmacokinetics of etodolac in the horse following oral and intravenous administration

Journal of Veterinary Pharmacology and Therapeutics

Volumn 30, Issue 1, 2007, Pages 43-48

  Davis, J L ^a   Papich, M G ^a   Morton, A J ^b   Gayle, J ^c   Blikslager, A T ^a   Campbell, N B ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c New England Equine Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ETODOLAC; PROSTAGLANDIN SYNTHASE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; MALE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; ETODOLAC; FEMALE; HORSES; INJECTIONS, INTRAVENOUS; MALE;

EQUIDAE; EQUUS CABALLUS;

EID: 33846060721     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2007.00811.x     Document Type: Article

References (38)

1. Beretta, C., Garavaglia, G. & Cavalli, M. (2005) COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacology Research, 52, 302-306.
2. Blikslager, A.T., Zimmel, D.N., Young, K.M., Campbell, N.B., Little, D. & Argenzio, R.A. (2002) Recovery of ischaemic injured porcine ileum: evidence for a contributory role of COX-1 and COX-2. Gut, 50, 615-623.
3. Boni, J., Korth-Bradley, J., McGoldrick, K., Appel, A. & Cooper, S. (1999) Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery. Journal of Clinical Pharmacology, 39, 729-737.
4. Brideau, C., Van Staden, C. & Chan, C.C. (2001) In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. American Journal of Veterinary Research, 62, 1755-1760.
5. Brocks, D.R. & Jamali, F. (1991) Enantioselective pharmacokinetics of etodolac in the rat: tissue distribution, tissue binding, and in vitro metabolism. Journal of Pharmaceutical Science, 80, 1058-1061.
6. Brocks, D.R. & Jamali, F. (1994) Etodolac clinical pharmacokinetics. Clinical Pharmacokinetics, 26, 259-274.
7. Budsberg, S.C., Johnston, S.A., Schwarz, P.D., DeCamp, C.E. & Claxton, R. (1999) Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. Journal of the American Veterinary Medical Association, 214, 206-210.
8. Campbell, N. & Blikslager, A.T. (2000) The role of cyclooxygenase inhibitors in repair of ischemic-injured jejunal mucosa in the horse. Equine Veterinary Journal Supplement, 32, 59-64.
9. Campbell, N.B., Jones, S.L. & Blikslager, A.T. (2002) The effects of cyclooxygenase inhibitors on bile-injured and normal equine colon. Equine Veterinary Journal, 34, 493-498.
10. Cayen, M.N., Kraml, M., Ferdinandi, E.S., Greselin, E. & Dvornik, D. (1981) The metabolic disposition of etodolac in rats, dogs, and man. Drug Metabolism Reviews, 12, 339-362.
11. Chandrasekharan, N.V., Dai, H., Roos, K.L., Evanson, N.K., Tomsik, J., Elton, T.S. & Simmons, D.L. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America. 99, 13926-13931.
12. Cohen, N.D., Carter, G.K., Mealey, R.H. & Taylor, T.S. (1995) Medical management of right dorsal colitis in 5 horses: a retrospective study (1987-1993). Journal of Veterinary Internal Medicine, 9, 272-276.
13. Demerson, C.A., Humber, L.G., Dobson, T.A. & Martel, R.R. (1975) Chemistry and antiinflammatory activities of prodolic-acid and related 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-alkanoic acids. 1. Journal of Medical Chemistry, 18, 189-191.
14. Dey, M., Enever, R., Kraml, M., Prue, D.G., Smith, D. & Weierstall, R. (1993) The dissolution and bioavailability of etodolac from capsules exposed to conditions of high relative humidity and temperatures. Pharmaceutical Research, 10, 1295-1300.
15. Dore, R., Ballard, I., Constantine, G. & McDonald, P. (1995) Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study. Clinical Therapeutics, 17, 656-666.
16. Emery, P., Zeidler, H., Kvien, T.K., Guslandi, M., Naudin, R., Stead, H., Verburg, K.M., Isakson, P.C., Hubbard, R.C. & Geis, G.S. (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet, 354, 2106-2111.
17. Goldstein, J.L., Silverstein, F.E., Agrawal, N.M., Hubbard, R.C., Kaiser, J., Maurath, C.J., Verburg, K.M. & Geis, G.S. (2000) Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. American Journal of Gastroenterology, 95, 1681-1690.
18. Gunson, D.E. & Soma, L.R. (1983) Renal papillary necrosis in horses after phenylbutazone and water deprivation. Veterinary Pathology, 20, 603-610.
19. Harris, R.C., McKanna, J.A., Akai, Y., Jacobson, H.R., Dubois, R.N. & Breyer, M.D. (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. Journal of Clinical Investigation, 94, 2504-2510.
20. Hla, T. & Neilson, K. (1992) Human cyclooxygenase-2 cDNA. Proceedings of the National Academy of Sciences of the United States of America. 89, 7384-7388.
21. Honda, K., Nakamura, A., Morino, A. & Nomura, A. (1991) Studies on the metabolic fate of etodolac (IV): stereoselective disposition of etodolac in rats. Iyakuhin Kenkyu, 22, 147-151.
22. Jackson, L.M., Wu, K.C., Mahida, Y.R., Jenkins, D. & Hawkey, C.J. (2000) Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut, 47, 762-770.
23. Jamali, F., Mehvar, R., Lemko, C. & Eradiri, O. (1998) Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans. Journal of Pharmaceutical Science, 77, 963-966.
24. Jones, C.J., Streppa, H.K., Harmon, B.G. & Budsberg, S.C. (2002) In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. American Journal of Veterinary Research, 63, 1527-1531.
25. Mizuno, H. (1997) Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology, 112, 387-397.
26. Moore, R.M. (1998) Non-steroidal anti-inflammatory drugs. In Current Techniques in Equine Surgery and Lameness, 2nd edn. Eds White, N., Moore, J.N.. pp. 25-30. WB Saunders, Philadelphia.
27. Morton, A.J., Campbell, N.B., Gayle, J.M., Redding, W.R. & Blikslager, A.T. (2005) Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis. Research in Veterinary Science, 78, 189-192.
28. Read, W.K. (1983) Renal medullary crest necrosis associated with phenylbutazone therapy in horses. Veterinary Pathology, 20, 662-669.
29. Riendeau, D., Percival, M.D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J.P., Friesen, R.W., Gordon, R., Greig, G., Guay, J., Mancini, J., Ouellet, M., Wong, E., Xu, L., Boyce, S., Visco, D., Girard, Y., Prasit, P., Zamboni, R., Rodger, I.W., Gresser, M., Ford-Hutchinson, A.W., Young, R.N. & Chan, C.C. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Journal of Pharmacology and Experimental Therapeutics, 296, 558-566.
30. Sakamoto, C. (1998) Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. Journal of Gastroenterology, 33, 618-624.
31. Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J. & Isakson, P. (1997) Distribution of COX-1 and COX-2 in normal and inflamed tissues. Advances in Experimental Medical Biology, 400A, 167-170.
32. Shah, V.P., Midha, K.K. & Dighe, S. (1992) Conference report: Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. International Journal of Pharmaceutics, 82, 1-7.
33. Simmons, T.R., Gaughan, E.M., Ducharme, N.G., Dill, S.G., King, J.M. & Anderson, W.I. (1990) Treatment of right dorsal ulcerative colitis in a horse. Journal of the American Veterinary Medical Association, 196, 455-458.
34. Simon, L.S., Weaver, A.L., Graham, D.Y., Kivitz, A.J., Lipsky, P.E., Hubbard, R.C., Isakson, P.C., Verburg, K.M., Yu, S.S., Zhao, W.W. & Geis, G.S. (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. Journal of the American Medical Association, 282, 1921-1928.
35. Symonds, K.D., MacAllister, C.G., Erkert, R.S. & Payton, M.E. (2006) Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome. American Journal of Veterinary Research, 67, 557-561.
36. Tomlinson, J.E., Wilder, B.O., Young, K.M. & Blikslager, A.T. (2004) Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. American Journal of Veterinary Research, 65, 761-769.
37. Van Hoogmoed, L.M., Snyder, J.R. & Harmon, F.A. (2002) In vitro investigation of the effects of cyclooxygenase)2 inhibitors on contractile activity of the equine dorsal and ventral colon. American Journal of Veterinary Research, 63, 1496-1500.
38. Vane, J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology, 231, 232-235.